
Neuraxpharm pays US$650m for MS drug commercialisation
Together with a fee of US$12.5m for the launch of the B cell suppressant antibody to treat relapsing/remitting mulitple sclerosis (rMS), the US$140m...

Carbios raises €141m to boost enzymatic PET recycling
Carbios has announced a capital increase of €141m in cash with preferential subscription rights through the issue of 5,558,695 new shares at a...

EG 427 expands Series A closing to €18m
EF 147, which got the additional €5m from undisclosed existing investors and new family office investors, is going to finance preclinical work upon...

Study: New breeding methods hardly contribute to climate protection
Up and down the country, national governments and the EU Commission (EC) are campaigning to facilitate the commercialisation of cis-gentic and...

Mithra Pharmaceuticals SA in €17m licencing deal
Donesta is the first Estetrol-based hormone substitution therapy for the relief of menopausal vasomotor symptoms (VMS). Under a licencing deal with...

Novo Nordisk takes over Inversago Pharma Inc.
As competiion for Novo Nordisk A/S’ subcutanously administered blockbuster GLP1-receptor blocker semaglutide is growing, particularly as an obesity...

Enzyme foams morer active and stable
So far, foamed enzymes changed their structure and thus function. However, the new method, for which a patent has been filed circumvents this...